100
Participants
Start Date
June 28, 2021
Primary Completion Date
September 30, 2025
Study Completion Date
June 30, 2026
IDX-1197+XELOX
The dose levels will be escalated following a 3+3 dose escalation scheme.
IDX-1197+Irinotecan
The dose levels will be escalated following a 3+3 dose escalation scheme.
NOT_YET_RECRUITING
Dong-A University Hospital, Busan
NOT_YET_RECRUITING
Hematology Oncology Clinic Baton Rouge / Sarah Cannon, Baton Rouge
RECRUITING
USC Norris Comp. Cancer Ctr Hospital, Los Angeles
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
Astera Cancer Care, East Brunswick
NOT_YET_RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou
NOT_YET_RECRUITING
Shanghai East Hospital, Shanghai
RECRUITING
Seoul National University Bundang Hospital, Seongnam
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital - Yonsei Cancer Center, Seoul
RECRUITING
Korea University Anam Hospital, Seoul
Idience Co., Ltd.
INDUSTRY